Table 2.
Main clinical and radiographic outcomes of poor and non-poor prognosis patients receiving initial monotherapy or initial combination therapy after 3 months and after 1 year
| Poor prognosis patients | |||
|---|---|---|---|
| Initial mono | Initial combo | P -value | |
| DAS remission | |||
| After 3 months | 5 (5) | 15 (17) | 0.016 |
| After 1 year | 21 (21) | 31 (36) | 0.034 |
| ACR20 response | |||
| After 3 months | 35 (38) | 57 (70) | < 0.001 |
| After 1 year | 73 (80) | 75 (93) | 0.026 |
| ACR50 response | |||
| After 3 months | 12 (13) | 40 (48) | <0.001 |
| After 1 year | 52 (57) | 59 (71) | 0.060 |
| ACR70 response | |||
| After 3 months | 4 (4) | 20 (24) | <0.001 |
| After 1 year | 28 (30) | 35 (44) | 0.081 |
| Decrease in HAQ score, median (IQR) | |||
| After 3 months | −0.38 (−0.63, 0.06) | −0.75 (−1.13, −0.25) | <0.001 |
| After 1 year | −0.75 (−1.13, −0.38) | −0.88 (−1.38, −0.38) | 0.110 |
| SHS progression | |||
| After 1 year, median (IQR) | 1.5 (0, 5.0) | 0 (0, 2.0) | 0.001 |
| RRP | 24 (26) | 8 (10) | 0.006 |
| Non-poor prognosis patients | |||
| Initial mono | Initial combo | P -value | |
| DAS remission | |||
| After 3 months | 7 (7) | 23 (18) | 0.017 |
| After 1 year | 35 (36) | 43 (36) | 1.000 |
| ACR20 response | |||
| After 3 months | 38 (44) | 79 (71) | <0.001 |
| After 1 year | 63 (72) | 96 (85) | 0.024 |
| ACR50 response | |||
| After 3 months | 12 (13) | 56 (49) | <0.001 |
| After 1 year | 44 (52) | 77 (68) | 0.027 |
| ACR70 response | |||
| After 3 months | 3 (3) | 20 (17) | 0.001 |
| After 1 year | 29 (33) | 45 (39) | 0.380 |
| Decrease in HAQ score, median (IQR) | |||
| After 3 months | −0.38 (−0.75, 0) | −0.63 (−1.13, −0.25) | <0.001 |
| After 1 year | −0.63 (−1.13, −0.13) | −0.88 (−1.25, −0.31) | 0.040 |
| SHS progression | |||
| After 1 year, median (IQR) | 0 (0, 1.5) | 0 (0, 1.0) | 0.451 |
| RRP | 10 (11) | 4 (4) | 0.054 |
Numbers indicate number of patients (percentage) unless indicated otherwise. ACR response: according to the American College of Rheumatology criteria [17]; DAS remission, disease activity score <1.6 [16]; Initial combo: initial combination therapy with either prednisone or infliximab; Initial mono: initial monotherapy with methotrexate; non-poor prognosis (presence of ≤2 of 4 poor prognostic factors); HAQ, health assessment questionnaire (scale 0 to 3); poor prognosis (presence of ≥3 of 4 poor prognostic factors); SHS, Sharp van der Heijde score; RRP, rapid radiographic progression, defined as increase in Sharp van der Heijde score ≥5 points during the first year.